DK3805220T3 - Polycykliske carbamoylpyridon-derivater til behandling af hiv - Google Patents

Polycykliske carbamoylpyridon-derivater til behandling af hiv Download PDF

Info

Publication number: DK3805220T3
Authority: DK; Denmark
Prior art keywords: hiv; treatment; polycyclic carbamoylpyridone; carbamoylpyridone derivatives; derivatives
Prior art date: 2018-05-31

Application number

DK19810498.6T

Other languages

English (en)

Inventor

Yoshiyuki Taoda

Yuto UNOH

Original Assignee

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-31

Filing date

2019-05-30

Publication date

2024-08-26

2019-05-30 Application filed by Shionogi & Co filed Critical Shionogi & Co

2024-08-26 Application granted granted Critical

2024-08-26 Publication of DK3805220T3 publication Critical patent/DK3805220T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK19810498.6T 2018-05-31 2019-05-30 Polycykliske carbamoylpyridon-derivater til behandling af hiv DK3805220T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2018104156		2018-05-31
PCT/JP2019/021446 WO2019230858A1 (ja)	2018-05-31	2019-05-30	多環性カルバモイルピリドン誘導体

Publications (1)

Publication Number	Publication Date
DK3805220T3 true DK3805220T3 (da)	2024-08-26

Family

ID=68698918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK19810498.6T DK3805220T3 (da)	2018-05-31	2019-05-30	Polycykliske carbamoylpyridon-derivater til behandling af hiv

Country Status (36)

Country	Link
US (3)	US11649236B2 (da)
EP (2)	EP4257137A3 (da)
JP (2)	JP7328962B2 (da)
KR (2)	KR20250002769A (da)
CN (2)	CN112513042B (da)
AR (1)	AR115455A1 (da)
AU (2)	AU2019277548B2 (da)
BR (1)	BR112020024077A2 (da)
CA (1)	CA3102063A1 (da)
CL (1)	CL2020003002A1 (da)
CO (1)	CO2020014294A2 (da)
CR (2)	CR20200644A (da)
DK (1)	DK3805220T3 (da)
DO (1)	DOP2020000221A (da)
EA (1)	EA202092921A1 (da)
ES (1)	ES2984245T3 (da)
FI (1)	FI3805220T3 (da)
HR (1)	HRP20241221T1 (da)
HU (1)	HUE068170T2 (da)
IL (2)	IL313474A (da)
LT (1)	LT3805220T (da)
MA (1)	MA52795B1 (da)
MD (1)	MD3805220T2 (da)
MX (2)	MX2020012176A (da)
MY (1)	MY198568A (da)
PE (2)	PE20210477A1 (da)
PH (1)	PH12020552000A1 (da)
PL (1)	PL3805220T3 (da)
PT (1)	PT3805220T (da)
RS (1)	RS65891B1 (da)
SG (1)	SG11202011382PA (da)
SI (1)	SI3805220T1 (da)
SM (1)	SMT202400330T1 (da)
UA (1)	UA129229C2 (da)
WO (1)	WO2019230858A1 (da)
ZA (1)	ZA202007567B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE059677T2 (hu)	2019-03-22	2022-12-28	Gilead Sciences Inc	Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
JP7776335B2 (ja) *	2019-11-28	2025-11-26	塩野義製薬株式会社	多環性ピリドピラジン誘導体
US20230059640A1 (en) *	2019-11-28	2023-02-23	Shionogi & Co., Ltd.	Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
EP4110783A1 (en)	2020-02-24	2023-01-04	Gilead Sciences, Inc.	Tetracyclic compounds for treating hiv infection
JP7407976B2 (ja) *	2020-05-21	2024-01-04	シーセンファーマシューティカルカンパニーリミテッド	縮合環誘導体及びその薬学的用途
EP4188379A4 (en) *	2020-07-27	2024-08-28	Merck Sharp & Dohme LLC	POLYCYCLIC CAP-DEPENDENT ENDONUCLEARANCE INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLUENZA
CA3192145A1 (en) *	2020-09-30	2022-04-07	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
PE20231297A1 (es)	2021-01-19	2023-08-22	Gilead Sciences Inc	Compuestos de piridotriazina sustituidos y usos de estos
CN117751118A (zh) *	2021-07-30	2024-03-22	吉斯凯(苏州)制药有限公司	大环吡啶酮类化合物及其应用
TW202446773A (zh)	2022-04-06	2024-12-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024061257A1 (zh) *	2022-09-20	2024-03-28	吉斯凯(苏州)制药有限公司	多环氮杂环酮类化合物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1549315A4 (en)	2002-09-11	2007-05-23	Merck & Co Inc	DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
MXPA05007010A (es)	2002-12-27	2005-08-18	Angeletti P Ist Richerche Bio	Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1852434B1 (en)	2005-02-21	2011-07-13	Shionogi Co., Ltd.	Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
LT3372281T (lt)	2005-04-28	2021-12-10	Viiv Healthcare Company	Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
BRPI0617842A2 (pt)	2005-10-27	2011-08-09	Shionogi & Co	composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
US10065950B2 (en)	2010-02-26	2018-09-04	Japan Tobacco Inc.	Substituted thiazoles as HIV integrase inhibitors
JP5766690B2 (ja)	2010-04-12	2015-08-19	塩野義製薬株式会社	インテグラーゼ阻害活性を有するピリドン誘導体
KR20140090197A (ko)	2011-10-12	2014-07-16	시오노기세야쿠 가부시키가이샤	인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체
WO2014099586A1 (en)	2012-12-17	2014-06-26	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as hiv integrase inhibitors
PH12019501848A1 (en)	2012-12-21	2020-03-02	Gilead Sciences Inc	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (en)	2012-12-27	2018-03-28	Japan Tobacco Inc.	SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2997033B1 (en)	2013-05-17	2017-11-15	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2014200880A1 (en) *	2013-06-13	2014-12-18	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (da)	2013-07-12	2018-07-21
WO2015006731A1 (en)	2013-07-12	2015-01-15	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
WO2015039348A1 (en)	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TN2016000090A1 (en)	2013-09-27	2017-07-05	Merck Sharp & Dohme	Substituted quinolizine derivatives useful as hiv integrase inhibitors.
WO2015089847A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015199167A1 (ja)	2014-06-25	2015-12-30	日本たばこ産業株式会社	置換されたスピロピリド［１，２－ａ］ピラジン誘導体の製造方法および中間体
JPWO2016027879A1 (ja)	2014-08-22	2017-06-01	塩野義製薬株式会社	インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016094198A1 (en)	2014-12-09	2016-06-16	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016090545A1 (en)	2014-12-09	2016-06-16	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) *	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3285582B1 (en)	2015-03-26	2020-11-11	Merck Sharp & Dohme Corp.	Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
BR112017020837A2 (pt)	2015-04-02	2018-07-03	Gilead Sciences, Inc.	compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
WO2016187788A1 (en)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3377065B1 (en)	2015-11-17	2022-05-18	Merck Sharp & Dohme Corp.	Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
US10548910B2 (en)	2015-11-17	2020-02-04	Merck Sharp & Dohme Corp.	Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017106071A1 (en)	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en)	2015-12-31	2017-07-06	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3548031B1 (en)	2016-12-02	2023-07-19	Merck Sharp & Dohme LLC	Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JOP20190130A1 (ar)	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2019160783A1 (en)	2018-02-15	2019-08-22	Merck Sharp & Dohme Corp.	Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3784241A4 (en)	2018-04-27	2022-01-19	Merck Sharp & Dohme Corp.	TETRACYCLIC HETEROCYCLENIC COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
US11453669B2 (en)	2018-05-31	2022-09-27	Shionogi & Co., Ltd.	Polycyclic pyridone derivative
WO2019236396A1 (en)	2018-06-05	2019-12-12	Merck Sharp & Dohme Corp.	Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CN108957755B (zh)	2018-07-27	2021-04-30	京东方科技集团股份有限公司	一种显示组件及其控制方法、平视显示器及汽车
HUE059677T2 (hu)	2019-03-22	2022-12-28	Gilead Sciences Inc	Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása

2019
- 2019-05-30 WO PCT/JP2019/021446 patent/WO2019230858A1/ja not_active Ceased
- 2019-05-30 JP JP2020522577A patent/JP7328962B2/ja active Active
- 2019-05-30 IL IL313474A patent/IL313474A/en unknown
- 2019-05-30 ES ES19810498T patent/ES2984245T3/es active Active
- 2019-05-30 MA MA52795A patent/MA52795B1/fr unknown
- 2019-05-30 AU AU2019277548A patent/AU2019277548B2/en active Active
- 2019-05-30 CN CN201980050399.5A patent/CN112513042B/zh active Active
- 2019-05-30 AR ARP190101467A patent/AR115455A1/es unknown
- 2019-05-30 KR KR1020247040377A patent/KR20250002769A/ko active Pending
- 2019-05-30 HR HRP20241221TT patent/HRP20241221T1/hr unknown
- 2019-05-30 RS RS20240971A patent/RS65891B1/sr unknown
- 2019-05-30 MX MX2020012176A patent/MX2020012176A/es unknown
- 2019-05-30 CR CR20200644A patent/CR20200644A/es unknown
- 2019-05-30 SI SI201930798T patent/SI3805220T1/sl unknown
- 2019-05-30 LT LTEPPCT/JP2019/021446T patent/LT3805220T/lt unknown
- 2019-05-30 PE PE2020001863A patent/PE20210477A1/es unknown
- 2019-05-30 PT PT198104986T patent/PT3805220T/pt unknown
- 2019-05-30 EP EP23192706.2A patent/EP4257137A3/en active Pending
- 2019-05-30 HU HUE19810498A patent/HUE068170T2/hu unknown
- 2019-05-30 BR BR112020024077-0A patent/BR112020024077A2/pt unknown
- 2019-05-30 IL IL279051A patent/IL279051B2/en unknown
- 2019-05-30 MD MDE20210334T patent/MD3805220T2/ro unknown
- 2019-05-30 CN CN202311258763.1A patent/CN117327072A/zh active Pending
- 2019-05-30 SG SG11202011382PA patent/SG11202011382PA/en unknown
- 2019-05-30 SM SM20240330T patent/SMT202400330T1/it unknown
- 2019-05-30 FI FIEP19810498.6T patent/FI3805220T3/fi active
- 2019-05-30 US US17/058,251 patent/US11649236B2/en active Active
- 2019-05-30 EP EP19810498.6A patent/EP3805220B1/en active Active
- 2019-05-30 KR KR1020207037580A patent/KR102741390B1/ko active Active
- 2019-05-30 UA UAA202008303A patent/UA129229C2/uk unknown
- 2019-05-30 CR CR20230571A patent/CR20230571A/es unknown
- 2019-05-30 CA CA3102063A patent/CA3102063A1/en active Pending
- 2019-05-30 DK DK19810498.6T patent/DK3805220T3/da active
- 2019-05-30 EA EA202092921A patent/EA202092921A1/ru unknown
- 2019-05-30 PE PE2025000789A patent/PE20251594A1/es unknown
- 2019-05-30 PL PL19810498.6T patent/PL3805220T3/pl unknown
- 2019-05-30 MY MYPI2020006045A patent/MY198568A/en unknown
2020
- 2020-11-13 MX MX2023010377A patent/MX2023010377A/es unknown
- 2020-11-18 CO CONC2020/0014294A patent/CO2020014294A2/es unknown
- 2020-11-18 CL CL2020003002A patent/CL2020003002A1/es unknown
- 2020-11-20 PH PH12020552000A patent/PH12020552000A1/en unknown
- 2020-11-27 DO DO2020000221A patent/DOP2020000221A/es unknown
- 2020-12-04 ZA ZA2020/07567A patent/ZA202007567B/en unknown
2023
- 2023-03-22 US US18/124,827 patent/US12139489B2/en active Active
- 2023-08-03 JP JP2023127333A patent/JP7679427B2/ja active Active
2024
- 2024-02-08 AU AU2024200783A patent/AU2024200783A1/en active Pending
- 2024-06-26 US US18/755,191 patent/US20240352015A1/en active Pending

Also Published As

Publication number	Publication date
US20230227454A1 (en)	2023-07-20
AU2019277548A1 (en)	2021-01-14
KR20250002769A (ko)	2025-01-07
US20210122751A1 (en)	2021-04-29
JP7679427B2 (ja)	2025-05-19
IL313474A (en)	2024-08-01
EP4257137A2 (en)	2023-10-11
HRP20241221T1 (hr)	2024-12-06
FI3805220T3 (fi)	2024-08-30
JPWO2019230858A1 (ja)	2021-06-24
JP2023145723A (ja)	2023-10-11
IL279051B2 (en)	2025-01-01
MX2020012176A (es)	2021-01-29
US12139489B2 (en)	2024-11-12
DOP2020000221A (es)	2021-03-15
EP3805220A4 (en)	2022-01-05
PT3805220T (pt)	2024-08-16
PH12020552000A1 (en)	2021-09-27
JP7328962B2 (ja)	2023-08-17
PE20251594A1 (es)	2025-06-16
EA202092921A1 (ru)	2021-04-07
CL2020003002A1 (es)	2021-04-16
AR115455A1 (es)	2021-01-20
AU2019277548B2 (en)	2023-12-14
LT3805220T (lt)	2024-08-26
EP3805220B1 (en)	2024-07-31
MX2023010377A (es)	2023-09-12
CR20200644A (es)	2021-02-05
BR112020024077A2 (pt)	2021-02-09
MY198568A (en)	2023-09-05
IL279051A (en)	2021-01-31
PE20210477A1 (es)	2021-03-11
SI3805220T1 (sl)	2024-10-30
ZA202007567B (en)	2022-04-28
CR20230571A (es)	2024-01-22
EP4257137A3 (en)	2023-11-01
CO2020014294A2 (es)	2020-12-21
MA52795B1 (fr)	2024-09-30
EP3805220A1 (en)	2021-04-14
UA129229C2 (uk)	2025-02-19
WO2019230858A1 (ja)	2019-12-05
CN117327072A (zh)	2024-01-02
HUE068170T2 (hu)	2024-12-28
PL3805220T3 (pl)	2024-11-04
CN112513042A (zh)	2021-03-16
CN112513042B (zh)	2023-09-29
IL279051B1 (en)	2024-09-01
ES2984245T3 (es)	2024-10-29
US20240352015A1 (en)	2024-10-24
CA3102063A1 (en)	2019-12-05
US11649236B2 (en)	2023-05-16
SG11202011382PA (en)	2020-12-30
KR102741390B1 (ko)	2024-12-10
RS65891B1 (sr)	2024-09-30
KR20210015922A (ko)	2021-02-10
AU2024200783A1 (en)	2024-02-29
MA52795A (fr)	2021-04-14
MD3805220T2 (ro)	2024-10-31
SMT202400330T1 (it)	2024-09-16

Publication	Publication Date	Title
DK3805220T3 (da)	2024-08-26	Polycykliske carbamoylpyridon-derivater til behandling af hiv
DK3728271T3 (da)	2022-12-19	Makrocykliske forbindelser til behandling af sygdomme
DK3570844T3 (da)	2023-11-13	Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3521282T3 (da)	2021-09-27	Quinazolinderivater anvendt til behandling af hiv
SI3347352T1 (sl)	2019-08-30	Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
DK3512850T3 (da)	2023-07-03	Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da)	2020-11-09	Inhibitorer af menin-mll-interaktionen
DK3668509T3 (da)	2023-02-20	Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
DK3668851T3 (da)	2022-03-28	Fremgangsmåde til fremstilling af thiocarbonater
DK3503890T3 (da)	2025-01-27	Anvendelse af pridopidin til behandling af dystonier
DK3504187T3 (da)	2025-04-14	Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3436074T3 (da)	2020-08-03	Thiazolidforbindelser til behandling af virale infektioner
IL282114A (en)	2021-05-31	Processes for preparing functionalized cyclooctenes
DK3573620T3 (da)	2023-03-20	Sammensætninger til behandling af hypertension
DK3280408T3 (da)	2020-02-03	Fremgangsmåde til fremstilling af dicycloplatin
DK3578562T3 (da)	2021-07-12	L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3468604T3 (da)	2021-04-19	Farmaceutiske kombinationer til behandling af cancer
DK3638293T3 (da)	2023-11-06	Sammensætninger til behandling af cancer
DK3724173T3 (da)	2022-01-03	Forbindelser til behandling af neuromuskulære lidelser
DK3331610T3 (da)	2021-05-10	Midler til anvendelse til behandling af gliom
DK3458467T3 (da)	2020-12-14	Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
DK3573948T3 (da)	2023-01-09	Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater
DK3506901T3 (da)	2021-06-21	Anvendelse af kynurensyre til behandling af muskelatrofi
DK3463328T3 (da)	2022-07-04	Seladelpar til behandling af primær biliær cholangitis